Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent grade III astrocytoma

Br J Neurosurg. 2013 Aug;27(4):516-8. doi: 10.3109/02688697.2013.764970. Epub 2013 Feb 8.

Abstract

A 15-year-old female presented with a middle cranial fossa anaplastic astrocytoma that was completely excised. She received local radiotherapy (54 Gy) and oral temozolomide. Five months after therapy, MRI showed local relapse. She underwent resection of the tumour with implantation of seven carmustine-impregnated wafers (Gliadel). She then received six cycles of procarbazine and lomustine therapy. Three years later, she is well and disease free. This case supports the further investigation of Gliadel in children and young people with relapsed high-grade glioma, particularly in the setting of a second complete resection.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Agents, Alkylating / pharmacology*
  • Astrocytoma* / drug therapy
  • Astrocytoma* / surgery
  • Carmustine / administration & dosage
  • Carmustine / pharmacology*
  • Combined Modality Therapy
  • Drug Implants
  • Female
  • Humans
  • Lomustine / administration & dosage
  • Lomustine / pharmacology*
  • Neoplasm Recurrence, Local* / drug therapy
  • Neoplasm Recurrence, Local* / surgery
  • Procarbazine / administration & dosage
  • Procarbazine / pharmacology*
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Alkylating
  • Drug Implants
  • Procarbazine
  • Lomustine
  • Carmustine